YSOPIA Bioscience Announces the Appointment of Dr. Jean-Pierre Lehner as New Chairman of the Board of Directors

Bordeaux, France, April 11^th, 2022 – YSOPIA Bioscience, a French clinical stage biotechnology company specializing in the research and development of innovative biotherapies based on the gut microbiome, is pleased to announce the appointment of Dr. Jean-Pierre Lehner as Chairman of the Board of Directors. In addition to his new role, Dr. Lehner has accompanied YSOPIA as  Chairman of the Scientific Advisory Board since 2018.

Dr. Lehner (MD, INSEAD) served the Pharmaceutical Industry during more than 30 years, where he developed a broad expertise in international clinical development and Medical Affairs. He has an extensive knowledge of Regulatory Affairs, with more than 30 Marketing Authorizations granted by the Food and Drug Administration (FDA) and/or European Medicines Agency (EMA).

As a member of Sanofi’s General Management and Research and Development committees, Jean-Pierre set up innovative approaches for clinical development based on real world data to strategize the clinical development of new products. Since he retired from Industry, Jean Pierre has acted as advisor to several startup companies, connecting them with investors. He is Board Member of several biotech companies in the EU and USA.

“I am happy to join YSOPIA’s Board of Directors in these exciting times with excellent first clinical results and several promising assets in the pipeline”, says Dr. Lehner. “YSOPIA is also accompanied by world-class scientific experts who reflect the Company’s cutting-edge technology. Hand-in-hand with the team, I am looking forward to contributing to YSOPIA’s development strategy.”

“We are thrilled to have Jean-Pierre join our Board of Directors as Chairman at this time in our company’s journey,” adds Fabrice Guez, Chief Executive Officer. “His impressive track record combined with his deep expertise in both pharma and biotech industries will have immediate and beneficial impacts on our strategy to deliver on our mission to bring innovative microbiome-based biotherapies to patients.”